Bayer A.G.OTCPK - Current
Wed, Oct. 26, 7:24 AM
Wed, Oct. 26, 3:49 AM
- Nintendo (OTCPK:NTDOY) revealed an operating loss of ¥5.95B in the period from March to September, while lowering its outlook and dividend.
- A hard landing! Airbus (OTCPK:EADSY) missed forecasts on supply chain issues, but the aircraft maker maintained its full year guidance.
- Brazil provided some bright side for Santander (NYSE:SAN) as a pick-up in performance lifted earnings above expectations, offsetting Brexit concerns.
- Provisions ate into the quarterly profit at Lloyds (NYSE:LYG), as the bank set aside another £1B to pay compensation for mis-sold payment protection insurance.
- Bayer (OTCPK:BAYRY) raised guidance for the full year on strong pharma results in its first quarterly scorecard since securing the Monsanto merger.
Tue, Sep. 20, 7:20 AM
- The Bayer Group (OTCPK:BAYRY) aims to achieve further growth in the coming years and is seeking higher sales and earnings in all businesses.
- Management Board Chairman Werner Baumann said, "We anticipate especially significant sales and margin growth at Pharmaceuticals. This growth is expected to be driven particularly by the positive development of our recently launched products, for which we now see combined peak sales potential of more than €10B.” At Crop Science, Bayer expects a substantial increase in the margin after closing of the planned acquisition of Monsanto.
- In Pharmaceuticals business, Bayer aspires to achieve average annual sales growth of ~6% by the end of 2018.Sales of this division totaled €15.3B in 2015 including the Radiology business. Bayer aims to increase the EBITDA margin before special items of Pharmaceuticals to between 32% and 34% in 2018 (2015: 30.1%). Six product candidates are expected to generate at least €6B in peak sales.
- In Consumer Health business, Bayer aims to grow average annual sales by between 4% and 5% by the end of 2018.
- In Crop Science business, Bayer expects above-market average annual sales growth in the coming years. Pro forma sales of the combined business of the Crop Science Division and Monsanto amounted to €23.1B in the calendar year 2015.
- In the Animal Health Business, Bayer aspires to grow sales of that business by between 4% and 5% yearly on average through the end of 2018.
Wed, Sep. 14, 6:50 AM
- Monsanto (NYSE:MON) has finally agreed to a takeover offer from Bayer (OTCPK:BAYRY), sources say, valuing it at $128 per share or a total of more than $66B.
- The deal would be the largest all-cash transaction on record and put a quarter of the combined world market for seeds and pesticides under one roof.
- Bayer has also settled on a $2B break-up fee for the deal, which is expected to close by the end of 2017.
- MON +1.7% premarket
Fri, Sep. 9, 9:47 AM
- Bayer, Monsanto deal likely to be announced late next week; price for Monsanto seen to be in high $120s, sources say.
- Still negotiating on regulatory issues.
- Source: CNBCNOW
Mon, Sep. 5, 2:18 AM
- Bayer's (OTCPK:BAYRY) supervisory board will discuss in a meeting on Sept. 14 whether to sweeten its offer for Monsanto (NYSE:MON) again or even pursue a hostile takeover, Germany's Rheinische Post reports.
- Sources told Reuters last month that the U.S. seed company had given its German suitor limited access to its books after turning down a sweetened $64B takeover offer.
Wed, Jul. 27, 9:04 AM
Fri, Jul. 15, 5:14 AM
- Even though Bayer (OTCPK:BAYRY) has sweetened the pot in its attempt to win Monsanto (NYSE:MON), analysts suggest the company is likely to reject the roughly $65B offer and could pursue other transactions such as combining with BASF's (OTCQX:BASFY) agro-chemicals unit.
- "I don't think they believe selling for $125 (per share) today is in the best interests of shareholders... and I do believe they are still considering being a consolidator and not a consolidee," said Chris Kapsch, analyst at BB&T Capital Markets.
Thu, Jul. 14, 9:00 AM
- Bayer (OTCPK:BAYZF)(OTCPK:BAYRY) announces that Aleve Direct Therapy, a drug-free wearable pain relief device, is now available over-the-counter at U.S. retailers nationwide. The product uses the same TENS (Transcutaneous Electrical Nerve Stimulation) technology used by doctors to provide consumers with deep penetrating relief at the source of lower back pain.
- Aleve Direct Therapy, an FDA-approved Class II medical device, is indicated for the temporary relief of pain associated with sore and aching muscles in the lower back due to strain from exercise or normal household and work activities.
Thu, Jul. 14, 3:54 AM
- BASF (OTCQX:BASFY) has declined to comment on a report Monsanto (NYSE:MON) is looking into a series of possible deals, including the potential acquisition of its agrochemicals unit.
- The news comes after Monsanto rejected a buyout offer from a different Germany company - Bayer (OTCPK:BAYRY) - back in May.
- BASF shares are in the green this morning, up 3% in Frankfurt, but the wider DAX is on the march higher too.
Fri, Jun. 24, 8:02 AM| Fri, Jun. 24, 8:02 AM | 5 Comments
Wed, Jun. 22, 7:50 AM
- Dupont (NYSE:DD) and Bayer (OTCPK:BAYRY) are teaming up to invest in a new fund that will back agricultural technology startups, becoming the latest companies to pile into the multibillion-dollar industry as farm profits shrink.
- Along with venture capital firm Finistere Ventures and others, the two firms have launched a $15M accelerator fund, called Radicle, that will back early-stage agricultural-tech companies.
Sun, May 22, 8:41 AM
- Now that Bayer's (OTCPK:BAYRY) bid for Monsanto (NYSE:MON) is out of the bag, attention has turned to how much the German company will need to pay for the seed giant.
- So far, neither side has disclosed the terms or structure of the takeover, but estimates compiled by Bloomberg range from $120-$150 a share, or a total value of up to $63B.
- Other concerns include how Bayer will finance the deal, keep its investment-grade rating, and stay on top of its non-agricultural businesses.
Wed, May 18, 9:52 PM
- Bayer (OTCPK:BAYRY) has made takeover overtures to Monsanto (NYSE:MON), The Wall Street Journal reports.
- Details were unclear, but a tie-up would result in the world's largest seed and crop-chemical company, with $67B in annual sales.
- Earlier, Monsanto's president and chief operating officer, Brett Begemann, called chatter about a takeover by Bayer or BASF "wild speculation because there's nothing there."
- Updated: A Monsanto statement says it's received an "unsolicited, non-binding proposal" from Bayer about a potential acquisition, and that the board is reviewing it in consultation with financial and legal advisers and won't comment otherwise.
- Now read Monsanto: Takeover Unlikely »
Wed, May 18, 2:35 PM
- Monsanto (MON -0.6%) slips as President and COO Brett Begemann says talk of a takeover by Bayer (OTCPK:BAYZF, OTCPK:BAYRY) or BASF (OTCQX:BASFY) is "wild speculation," and MON is staying focused on its own strategy.
- "It's all wild speculation because there’s nothing there," the COO tells Reuters at a BMO investor conference in New York.
- MON also says it expects farmers to plant its Xtend soybeans on more than 15M acres in North America next year, and believes the EU will approve imports by late summer or early fall.
- Now read Monsanto suspends new soybean technologies in Argentina
Thu, May 12, 3:37 PM
- Monsanto (MON +8.5%) remains sharply higher though off highs of the day, following headlines that Bayer (OTCPK:BAYRY -4.1%) and BASF (OTCQX:BASFY -1.7%) are considering a possible acquisition of the company.
- Financial Times reports that MON is interested in forming some sort of combination with the agrochemical businesses of either of the two companies but opposes any deal that would turn it into a division of a German company.
- Piper Jaffray analysts say the interest in acquiring MON is mere speculation, seeing a potential joint venture as a more likely outcome as "we believe Monsanto remains committed to building a chemistry business."
- J.P. Morgan believes Bayer would need to raise equity given the size of the deal, and thinks Bayer investors likely would be only lukewarm around the potential deal given limited accretion and investor desire for Bayer to strength its pharma pipeline following recent setbacks.
- Analysts say a MON takeover likely would draw intense scrutiny from global regulators already confronting an unprecedented wave of consolidation in the crop chemicals industry involving the likes of Dow Chemical (DOW +0.8%), DuPont (DD +0.2%) and Syngenta (SYT +0.4%).
- Now read Seed war sparked: Bayer and BASF to battle over Monsanto?